Announcements Trials

Browse Landscape

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 14 Colorectal Neoplasms 9 Neoplasm Metastasis 3 Leukemia, Myeloid, Acute 3 Sarcoma, Ewing 2 Rectal Neoplasms 2 Myelodysplastic Syndromes 2 Liver Neoplasms 2 Colonic Neoplasms 2 Carcinoma, Hepatocellular 2 Wilms Tumor 1 Thrombocytosis 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Rhabdomyosarcoma 1 Renal Insufficiency 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Pretreated Metastatic Colorectal Cancer 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Neuroblastoma 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Multiple Myeloma 1 Metastatic Solid Malignancies 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

Nivolumab 8 Paclitaxel 6 Sirolimus 5 Bevacizumab 5 temsirolimus 4 Pemetrexed 4 Ipilimumab 4 Docetaxel 4 Carboplatin 4 ARRY-334543 4 Gemcitabine 3 Erlotinib Hydrochloride 3 olaparib 2 linrodostat 2 apatinib 2 anlotinib 2 abemaciclib 2 Vorinostat 2 Sunitinib 2 Magnetic Resonance Spectroscopy 2 Irinotecan 2 Everolimus 2 Doxorubicin 2 Dasatinib 2 Chlorogenic Acid 2 Cetuximab 2 6-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2 vorolanib 1 vistusertib 1 trametinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Advanced Cancer × regorafenib × Clear all

NCT03475251 2022-02-18

A Study of CS1003 in Subjects With Advanced Solid Tumors

CStone Pharmaceuticals

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡